Home » Stocks » Akero Therapeutics

Akero Therapeutics, Inc. (AKRO)

Stock Price: $33.02 USD -0.35 (-1.05%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 946.80M
Revenue (ttm) n/a
Net Income (ttm) -50.28M
Shares Out 28.67M
EPS (ttm) -2.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $33.02
Previous Close $33.37
Change ($) -0.35
Change (%) -1.05%
Day's Open 32.85
Day's Range 31.03 - 33.79
Day's Volume 552,317
52-Week Range 10.78 - 35.30

More Stats

Market Cap 946.80M
Enterprise Value 821.52M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.67M
Float 10.92M
EPS (basic) -3.43
EPS (diluted) -2.27
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 515,664
Short Ratio 2.96
Short % of Float 3.97%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.42
Revenue n/a
Operating Income -52.52M
Net Income -50.28M
Free Cash Flow n/a
Net Cash 125.29M
Net Cash / Share 4.37
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -33.04%
ROE -53.49%
ROIC -159.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(60.51% upside)
Current: 33.02
Target: 53.00
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-45.65-13.78-4.56
Net Income-43.76-81.71-4.56
Shares Outstanding15.070.10-
Earnings Per Share-2.90-795.28-
Operating Cash Flow-35.63-4.63-4.38
Free Cash Flow-35.63-4.63-4.38
Cash & Equivalents13675.980.62
Net Cash / Debt13675.980.62
Book Value129-49.92-4.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akero Therapeutics, Inc.
Country United States
Employees 13
CEO Andrew Cheng

Stock Information

Ticker Symbol AKRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKRO


Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.